The COVID-19 Pandemic – Products

Thermo Fisher Scientific has introduced the Invitrogen Vivofectamine™ Delivery Solutions to provide high-performance lipid nanoparticles (LNP) technology for non-viral delivery of nucleic acids.

Oxford Nanopore, announced a landmark strategic partnership with the UK Government. This partnership brings together the UK’s world-class scientific organisations Genomics England, UK Biobank and NHS England, alongside Oxford Nanopore.

This whitepaper evaluates the results of a study into the three main capping options available to manufacturers, highlighting expert insights on mRNA capping costs and customer needs.

Just – Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD’s Manufacturing Optimization Program.

New binders will be developed to multiple waterborne pathogens. Optimer will support continuous water monitoring for rapid detection.

PCR/qPCR solution will support surveillance and monitoring of the current H5N1 strain of bird flu in response to multi-state outbreak in U.S. dairy cows.

Zapnometinib is now ready for clinical development in severe influenza, an area without approved therapies and with a rapidly evolving pandemic threat from bird flu virus H5N1.

Fluidic Sciences Ltd., announces its official launch as a company, and the commercial relaunch of the acquired Fluidity One-M instrument for measuring protein-protein interactions in solution—leveraging Microfluidic Diffusional Sizing (MDS) technology.

TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) has announced the grand opening of its new cGMP mRNA manufacturing facility.

China shifts its focus to thermal imaging technologies, securing 50% of worldwide shipments in 2023.